Targeting Age-Associated NAD⁺ Decline: in silico Evaluation of Minocycline as an Inhibitor of CD38 and PARP2
Authors:
- Oluwasegun Davis OlatomideOOOluwasegun Davis Olatomide
- Sunday Abraham MusaSMSunday Abraham Musa
- Zainab Mahmood BauchiZBZainab Mahmood Bauchi
- Sohnap James SamboSSSohnap James Sambo
- Abel Nosereme AgbonAAAbel Nosereme Agbon
- Akinyemi Ademola OmoniyiAOAkinyemi Ademola Omoniyi
- Amos Olalekan AbolajiAAAmos Olalekan Abolaji
Preprint
- 29 August 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Chronic activation of enzymes that require NAD⁺ for their activity such as CD38 and PARPs accelerates its decline with age, impairing cellular metabolism and contributing to degenerative processes. Targeting these enzymes may help preserve NAD⁺ levels and delay ageing-related pathologies. This study investigated the potential inhibitory activity of minocycline against CD38 and PARP2 using in silico approaches. Structures of minocycline and standard inhibitors for CD38 and PARPs were obtained from PubChem, while protein structures were retrieved from the Protein Data Bank (PDB). The ligands were docked against the protein using PyRx, and ligand-protein interactions were visualized with Discovery Studio Visualizer. Pharmacokinetic properties were assessed via pkCSM, toxicity was predicted using ProTox, and membrane permeability evaluated using PerMM. Ligands with favourable docking scores were further subjected to molecular dynamics (MD) simulations over a 100 ns trajectory. Minocycline demonstrated higher binding affinity for CD38 (− 8.9 kcal/mol) and PARP2 (− 10.2 kcal/mol) compared to their respective standard inhibitors (− 8.4 and − 10.1 kcal/mol). MD simulations revealed that minocycline formed more stable complexes with both targets, as indicated by lower root mean square deviation (RMSD) and root mean square fluctuation (RMSF) values. Radius of gyration analysis confirmed compact and stable protein-ligand complexes. These results suggest that minocycline may inhibit NAD⁺ consumers more effectively than existing inhibitors, potentially preserving NAD⁺ levels and mitigating the ageing process. The findings support the rationale for repurposing minocycline as a multi-target anti-ageing therapeutic.Keywords
All Related Versions
Funding Information
- Tertiary Education Trust Fund (TETF/DR&D/UNI/ZARIA/IBR/2020/VOL.1/53)
This publication has 67 references indexed in Scilit:
- Protein–ligand molecular dynamics simulation (PL-MDS), ADMET analyses, and bioactivity studies of phytochemicals from Aloe Vera: an In-Silico novel antidiabetics drug discovery effortDiscover Chemistry, 2025
- RETRACTED ARTICLE: Computational investigation of microbial nicotine derivatives as potential pesticidesDiscover Chemistry, 2025
- Development of novel strategies against the threats of drug-resistant Escherichia coli: an in silico and in vitro investigation3 Biotech, 2025
- Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative DiseasesNeuroscience Bulletin, 2023
- Phytocompounds of Onion Target Heat Shock Proteins (HSP70s) to Control Breast Cancer MalignancyApplied Biochemistry and Biotechnology, 2022
- Minocycline treatment improves proteostasis during Drosophila aging via autophagy mediated by FOXO and Hsp70Biomedicine & Pharmacotherapy, 2022
- Chronic minocycline treatment exerts antidepressant effect, inhibits neuroinflammation, and modulates gut microbiota in micePsychopharmacology, 2020
- Mechanisms of DNA damage, repair, and mutagenesisEnvironmental and Molecular Mutagenesis, 2017
- Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral IschemiaNeurochemical Research, 2016
- Permeability of the Blood–Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important CompoundsThe Journal of Membrane Biology, 2015